Apatinib shows antitumor in patients with malignant melanoma
The oral small molecule anti-angiogenesis inhibitor, apatinib, demonstrated antitumor activity as e second or above line therapy in patients with malignant melanoma with manageable toxicity, according to a study.
In this single-arm, single-center phase 2 trial, 15 patients (V660E BRAF status: 2 mutation, 2 unknown, 11 wild type) with malignant melanoma who had previously received ≥1 first-line therapy were treated with oral apatinib (500 mg) daily.
The median progression-free survival was 4.0 months. The researcher noted 2 major objective responses, resulting in a 13.3% response rate. The disease control rate was 86.7%, with 11 patients having stable disease. The median overall survival was 12 months.
The most common treatment-related adverse events of any grade were:
-Hypertension (80%)
-Mucositis oral (33.3%)
-Hand-foot skin reaction (26.7%)
-Liver function abnormalities (20%)
-Hemorrhage (20%)
-Diarrhea (20%)
Two patients experienced grade ≥3 treatment-related adverse effects including hypertension (6.7%) and mucositis (6.7%).
Reference
Yuan S, Fu Q, Zhao L, et al. Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma. Oncologist. 2022;oyab068. doi: 10.1093/oncolo/oyab068. Epub ahead of print. PMID: 35348754.
–Kelsey Moroz
